Want to see RGEN full AI Analyst Report?
RGEN Stock Chart & Stats
$131.96
-$5.64(-4.10%)
At close: 4:00 PM EDT
$131.96
-$5.64(-4.10%)
Day’s Range― - ―
52-Week Range$100.99 - $188.73
Previous CloseN/A
Volume1.36M
Average Volume (3M)1.14M
Market Cap
$10.17B
Enterprise Value$7.61K
Total Cash (Recent Filing)$810.45M
Total Debt (Recent Filing)$690.94M
Price to Earnings (P/E)244.8
Beta1.29
Next Earnings
Nov 03, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding56,435,620
10 Day Avg. Volume1,377,252
30 Day Avg. Volume1,139,495
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$173.82Price Target Upside31.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)2.06
Revenue Forecast (FY)$827.48M
Bulls Say, Bears Say
Bulls Say
Broad Revenue Growth And Franchise MomentumGrowth is broad across key franchises and customer groups rather than concentrated in one product. This supports durable demand for bioprocessing consumables, analytics and chromatography as biologics production and capacity expansion continue.
Margin Expansion And Improved Earnings OutlookImproving gross and operating margins indicate operating leverage and better profitability after the industry slowdown. The raised earnings outlook provides evidence that recovery is translating into stronger financial performance, not just higher sales.
Strong Cash Generation And Financial FlexibilityResilient positive free cash flow and a substantial cash balance give Repligen flexibility to fund research, capacity, acquisitions and transformation initiatives. Manageable leverage further reduces balance-sheet risk during demand or integration volatility.
Bears Say
Recovery Remains Below Prior Profitability ConsistencyThe earnings recovery has not yet restored the consistency or profitability achieved at the prior cycle peak. Modest returns on equity suggest that the asset and equity base is still generating limited shareholder returns, leaving execution important.
Margin Normalization And Transformation CostsSome recent margin gains may not persist as favorable production timing fades, creating a tougher comparison through 2026. Planned transformation charges add a recurring execution burden and could delay the full benefit of efficiency initiatives.
Competition And Customer Timing Create Execution RiskLarge equipment revenue can remain lumpy when customers delay facility decisions, reducing visibility across the bioprocessing cycle. In China, local competitors and the delayed partnership ramp may pressure growth and require sustained localization investment.
Repligen News
RGEN FAQ
What was Repligen’s price range in the past 12 months?
Repligen lowest stock price was $100.99 and its highest was $188.73 in the past 12 months.
What is Repligen’s market cap?
Repligen’s market cap is $10.17B.
When is Repligen’s upcoming earnings report date?
Repligen’s upcoming earnings report date is Nov 03, 2026 which is in 73 days.
How were Repligen’s earnings last quarter?
Repligen released its earnings results on Jul 28, 2026. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.447 by $0.093.
Is Repligen overvalued?
According to Wall Street analysts Repligen’s price is currently Undervalued.
Does Repligen pay dividends?
Repligen does not currently pay dividends.
What is Repligen’s EPS estimate?
Repligen’s EPS estimate is 0.46.
How many shares outstanding does Repligen have?
Repligen has 56,435,620 shares outstanding.
What happened to Repligen’s price movement after its last earnings report?
Repligen reported an EPS of $0.54 in its last earnings report, beating expectations of $0.447. Following the earnings report the stock price went up 10.896%.
Which hedge fund is a major shareholder of Repligen?
Currently, no hedge funds are holding shares in RGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$173.82 (31.72% Upside)
$173.82 (31.72% Upside)
Blogger Sentiment
Neutral
RGEN Sentiment 50%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 713.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.67%
Trailing 12-Months
Company Description
Repligen
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGEN Company Deck
RGEN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: the company reported healthy top-line growth ($194M, +15% reported, +11% organic), notable margin expansion (gross margin +180 bps, operating margin +160 bps), strong franchise performances (Analytics +50%+, Chromatography >25%, Proteins mid-teens), solid cash position ($785M), and raised adjusted EPS guidance. Management launched a transformation office targeting at least 1 point of annualized margin benefit by end of 2027 and announced a strategic OEM partnership in China. Key headwinds are mostly timing and structural: divestiture of a loss-making Polymem reduced revenue (~$7M), ATF/gene therapy customer timing moderated near-term growth (expected to rebound in 2027), some Q1 margin benefits may normalize, and there is execution risk around customer readiness for capital equipment and competition in China. Overall, positives (growth, margins, guidance, strategic initiatives, cash) materially outweigh the manageable lowlights tied to timing, one-off costs, and a small divestiture impact.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$173.82
▲(31.72% Upside)
Technical Analysis
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
0.68% Insiders
42.62% Mutual Funds
15.87% Other Institutional Investors
18.46% Public Companies and
Individual Investors